Tranquil Clinical Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Tranquil Clinical Research is a privately-held, Houston-based CRO founded in 2015, focusing on early-phase (Phase I) clinical research and neuroscience. It operates a 24/7, hospital-based Phase I unit for First-in-Human (FIH) trials and offers a full suite of CRO services, including its distinctive 'Tranquil Triumph' Functional Service Provider (FSP) and Sponsor Oversight partnership model. The company serves a global clientele of pharma, biotech, and device companies, leveraging over 30 years of collective team experience to manage and oversee clinical trials. Its value proposition centers on providing high-quality, integrated oversight and execution to ensure sponsor trials are conducted with integrity and performance excellence.

Neuroscience

Technology Platform

Integrated CRO service model featuring a 24/7 hospital-based Phase I unit for First-in-Human trials, full-service CRO capabilities, a Functional Service Provider (FSP) division ('Tranquil Triumph'), and a specialized Sponsor Oversight partnership model for managing and auditing other CROs.

Opportunities

Growing demand for specialized early-phase CRO services, particularly for complex First-in-Human trials.

Increasing industry adoption of Functional Service Provider (FSP) and independent sponsor oversight models, which are core offerings.

The continued rise of virtual biotech companies lacking internal clinical operations creates a strong client base for full-service providers.

Risk Factors

High competition from large, global CROs with greater resources and scale.

Revenue dependency on winning discrete project-based contracts, leading to potential cyclicality.

Significant operational and regulatory risk inherent in managing clinical trials, where any failure in safety or compliance could be catastrophic for reputation.

Competitive Landscape

Operates in the highly competitive global CRO market, dominated by large players like IQVIA, ICON, and Labcorp. Competes by offering niche specialization in early-phase trials and a high-touch, integrated oversight model rather than scale. Also competes with other specialized and regional CROs for sponsor contracts, differentiating on its dedicated Phase I unit and quality-focused culture.

More companies in Digital Health & Biotech SaaS →More companies in United States →